Novartis Ag (NVS) Notes Payables (2017 - 2025)

Novartis Ag's Notes Payables history runs 9 years deep, the most recent figure standing at $682.0 million for Q4 2025.

• In Q4 2025, Notes Payables rose 6.23% year-over-year to $682.0 million; the TTM figure through Dec 2025 stood at $682.0 million (up 6.23% YoY), while the FY2025 annual figure was $682.0 million, up 6.23% from the prior year.
• Notes Payables came in at $682.0 million for Q4 2025 at Novartis Ag, up from $642.0 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $899.0 million in Q4 2021 to a low of $624.0 million in Q4 2023.
• A 5-year average of $742.0 million and a median of $682.0 million in 2025 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables declined 27.69% in 2023 and advanced 6.23% in 2025, its largest moves.
• Novartis Ag's Notes Payables stood at $899.0 million in 2021, then dropped by 4.0% to $863.0 million in 2022, then dropped by 27.69% to $624.0 million in 2023, then gained by 2.88% to $642.0 million in 2024, then climbed by 6.23% to $682.0 million in 2025.
• According to Business Quant data, Notes Payables over the past three periods registered $682.0 million, $642.0 million, and $624.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison